BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 26490317)

  • 21. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
    Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.
    Poulain S; Roumier C; Galiègue-Zouitina S; Daudignon A; Herbaux C; Aiijou R; Lainelle A; Broucqsault N; Bertrand E; Manier S; Renneville A; Soenen V; Tricot S; Roche-Lestienne C; Duthilleul P; Preudhomme C; Quesnel B; Morel P; Leleu X
    Am J Hematol; 2013 Nov; 88(11):948-54. PubMed ID: 23861223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 24. Cell-free DNA analysis for detection of MYD88
    Demos MG; Hunter ZR; Xu L; Tsakmaklis N; Kofides A; Munshi M; Liu X; Guerrera ML; Leventoff CR; White TP; Flynn CA; Meid K; Patterson CJ; Yang G; Branagan AR; Sarosiek S; Castillo JJ; Treon SP; Gustine JN
    Am J Hematol; 2021 Jul; 96(7):E250-E253. PubMed ID: 33819355
    [No Abstract]   [Full Text] [Related]  

  • 25.
    Guerrera ML; Tsakmaklis N; Xu L; Yang G; Demos M; Kofides A; Chan GG; Manning RJ; Liu X; Chen JG; Munshi M; Patterson CJ; Castillo JJ; Dubeau T; Gustine J; Carrasco RD; Arcaini L; Varettoni M; Cazzola M; Treon SP; Hunter ZR
    Haematologica; 2018 Sep; 103(9):e408-e411. PubMed ID: 29599202
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
    Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
    Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
    Østergaard S; Schejbel L; Breinholt MF; Pedersen MØ; Hammer T; Munksgaard L; Nørgaard P; Høgdall E; Gjerdrum LMR; Nielsen TH
    Leuk Lymphoma; 2024 Jun; 65(6):758-767. PubMed ID: 38340359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
    Gustine JN; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ; Xu L
    Br J Haematol; 2019 Jan; 184(2):242-245. PubMed ID: 30183082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
    Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
    Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
    Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
    Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
    Growkova K; Kufová Z; Sevcikova T; Filipová J; Kascak M; Jelínek T; Grosicki S; Barchnicka A; Roziaková Ľ; Mistrík M; Simicek M; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):81-91. PubMed ID: 28903575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
    Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
    J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.
    Sacco A; Fenotti A; Affò L; Bazzana S; Russo D; Presta M; Malagola M; Anastasia A; Motta M; Patterson CJ; Rossi G; Imberti L; Treon SP; Ghobrial IM; Roccaro AM
    Oncotarget; 2017 May; 8(21):35435-35444. PubMed ID: 28423722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.
    Kapoor P; Ansell SM; Braggio E
    Cancer Treat Res; 2016; 169():321-361. PubMed ID: 27696269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Waldenstrom macroglobulinemia: genetics dictates clinical course.
    Lenz G
    Blood; 2014 May; 123(18):2750-1. PubMed ID: 24786453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia.
    Gustine JN; Xu L; Yang G; Liu X; Kofides A; Tsakmaklis N; Munshi M; Demos M; Guerrera ML; Meid K; Patterson CJ; Sarosiek S; Branagan AR; Hunter ZR; Castillo JJ; Treon SP
    Br J Haematol; 2021 Aug; 194(4):730-733. PubMed ID: 33713429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression.
    Hiemcke-Jiwa LS; Leguit RJ; Jiwa NM; Huibers MMH; Minnema MC
    Br J Haematol; 2019 Jun; 185(5):966-969. PubMed ID: 30408147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.